DANVERS, Mass.—Cell Signaling Technology, Inc. (CST), announced that it has entered into a new partnership agreement with Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics. Under the new agreement, CST will develop antibodies for kinase activation and protein phosphorylation assays that will be commercialized in Bio-Rad’s multiplex bead-based assays for the Bio-Plex(R) suspension array system. CST’s scientific and technical expertise will be leveraged to develop a broader array of antibodies for Bio-Rad’s Bio-Plex(R) platform, enabling multiplexed measurement of phosphoproteins and signaling pathways. Bio-Plex(R) phosphoprotein assays are optimized for simultaneous assessment of kinase and signaling protein activation states and provide critical tools for disease research and drug development. Given the complexity of cellular signaling and the diversity of mechanistic abnormalities underlying disease, Bio-Plex(R) multiplexed phosphoprotein assays can facilitate the understanding of disease and the development of more effective targeted therapeutic strategies.